论文部分内容阅读
目的探讨不同药物防治儿童过敏性哮喘发作的临床疗效。方法 2009年1月—2011年1月将80例轻中度过敏性哮喘患儿随机分为治疗组45例与对照组35例,两组患儿按全球哮喘防治方案进行分级基本治疗,治疗组加用孟鲁司特钠咀嚼片,对照组加用氯雷他定片,12周后比较两组疗效、复发情况、EOS、FEV1与PEF的变化。结果总有效率治疗组为95.56%,对照组为80.00%,比较差异有统计学意义(P<0.05);治疗组患儿哮喘缓解时间及肺部体征消失时间均明显短于对照组,且差异均有统计学意义(均P<0.05);治疗后两组EOS、FEV1、PEF比较差异均有统计学意义(均P<0.05)。结论孟鲁司特钠咀嚼片可作为过敏性哮喘患儿全球哮喘防治方案重要的辅助治疗药物,值得推广应用。
Objective To investigate the clinical effects of different drugs on the prevention and treatment of childhood allergic asthma. Methods From January 2009 to January 2011, 80 children with mild to moderate allergic asthma were randomly divided into treatment group (n = 45) and control group (n = 35). The two groups were treated according to the global asthma prevention and treatment plan. The treatment group Plus montelukast sodium chewable tablets, the control group plus loratadine tablets, 12 weeks after the two groups were compared efficacy, recurrence, EOS, FEV1 and PEF changes. Results The total effective rate was 95.56% in the treatment group and 80.00% in the control group, the difference was statistically significant (P <0.05); the asthma relief time and the disappearance time of the lung signs in the treatment group were significantly shorter than those in the control group (All P <0.05). There was significant difference in EOS, FEV1 and PEF between the two groups after treatment (both P <0.05). Conclusion Montelukast sodium chewable tablets can be used as an adjunctive therapy for global asthma in children with allergic asthma, which is worth popularizing and applying.